Head and neck squamous cell carcinoma (HNSCC) is a common cancer. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) is a widely used imaging modality in HNSCC.
Purpose
To provide evident data about associations between 18F-FDG PET and histopathology in HNSCC.
Material and Methods
The MEDLINE database was screened for associations between maximum standard uptake values (SUVmax) derived from 18F-FDG PET and histopathological features in HNSCC up to May 2020. Only papers containing correlation coefficients between SUVmax and histopathology were acquired. Overall, 23 publications were collected.
Results
The following correlations were calculated: KI 67: 12 studies (345 patients), pooled correlation coefficient (PCC): 0.23 (95% confidence interval [CI] 0.06–0.40); hypoxia-inducible factor-1α: eight studies (240 patients), PCC: 0.24 (95% CI 0.06–0.42); microvessel density: three studies (64 patients), PCC: 0.33 (95% CI 0.02–0.65); vascular endothelial growth factor: two studies (59 cases), PCC: 0.27 (95% CI 0.02–0.51); tumor suppressor protein p53: four studies (159 patients), PCC: 0.05 (95% CI –0.41 to 0.51); epidermal growth factor receptor: two studies (124 patients), PCC: 0.21 (95% CI 0.05–0.37); tumor cell count: three studies (67 patients), PCC: 0.18 (95% CI –0.06 to 0.42); tumor cell apoptosis: two studies (40 patients), PCC: 0.07 (95% CI = –0.85 to 0.99); B-cell lymphoma-2 protein: two studies (118 patients); PCC: 0.04 (95% CI –0.65 to 0.74); glucose-transporter 1: 10 studies (317 patients), PCC: 0.20 (95% CI 0.10–0.30).
Conclusion
SUVmax derived from 18F-FDG PET cannot reflect relevant histopathological features in HNSCC.
MarurSForastiereAA.Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc2016;
91:386–396.
2.
GoelRMooreWSumerB, et al.
Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. AJR Am J Roentgenol2017;
209:289–303.
3.
RyuISRohJLKimJS, et al.
Impact of (18)F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study. Eur J Cancer2016;
63:88–96.
4.
LiSJGuoWRenGXHuangG, et al.
Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. Br J Oral Maxillofac Surg2008;
46:180–186.
5.
KimSYRohJLKimJS, et al.
Utility of FDG PET in patients with squamous cell carcinomas of the oral cavity. Eur J Surg Oncol2008;
34:208–215.
6.
CastelliJDe BariBDepeursingeA, et al.
Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy. Crit Rev Oncol Hematol2016;
108:40–51.
7.
AbgralRKeromnesNRobinP, et al.
Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging2014;
41:659–667.
8.
DeronPVangestelCGoethalsI, et al.
FDG uptake in primary squamous cell carcinoma of the head and neck. The relationship between over expression of glucose transporters and hexokinases, tumour proliferation and apoptosis. Nuklearmedizin2011;
50:15–21.
9.
EryilmazACengizABasalY, et al.
The correlation of prognostic biomarkers (Ki-67, Bcl-2, HIF-1α, cyclin D1) with metabolic tumor volume measured by F-FDG PET/CT inlaryngeal cancer. J Cancer Res Ther2018;
14:994–998.
10.
GrönroosTJLehtiöKSöderströmKO, et al.
Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer2014;
14:876.
11.
HanMWLeeHJChoKJ, et al.
Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck2012;
34:1395–1402.
12.
HoshikawaHNishiyamaYKishinoT, et al.
Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers. Mol Imaging Biol2011;
13:172–177.
13.
JacobRWelkoborskyHJMannWJ, et al. [
Fluorine-18] Fluorodeoxyglucose Positron Emission Tomography, DNA Ploidy and Growth Fraction in Squamous-Cell Carcinomas of the Head and Neck. ORL J Otorhinolaryngol Relat Spec2001;
63:307–313.
14.
KimMAchmadAHiguchiT, et al.
Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma. J Nucl Med2015;
56:16–21.
15.
KitagawaYSanoKNishizawaS, et al.
FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging2003;
30:63–71.
16.
LinYCChenRYChenSW, et al.
Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes. Clin Otolaryngol2017;
42:608–619.
17.
LineckerAKermerCSulzbacherI, et al.
Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin2008;
47:80–85.
18.
MiyashitaGHiguchiTOriuchiN, et al.
18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry. Ann Nucl Med2010;
24:579–584.
19.
MiyawakiAIkedaRHijiokaH, et al.
SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma. Oncol Rep2010;
23:1205–1212.
20.
NorikaneTYamamotoYMaedaY, et al.
Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET. Nucl Med Commun2014;
35:30–35.
21.
RasmussenG BVogeliusIRRasmussenJH, et al.
Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. Acta Oncol2015;
54:1408–1415.
22.
Samolyk-KogaczewskaNSierkoEDziemianczyk-PakielaD, et al.
Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients.Cancers (Basel) 2020;
12:E511.
23.
ShimomuraHSasahiraTYamanakaY, et al. [
18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma. Int J Clin Oncol2015;
20:308–316.
24.
Surov A, Meyer HJ, Höhn AK, Winter K, Sabri O, Purz S. Associations between [18F]FDG-PET and complex histopathological parameters including tumor cell count and expression of KI 67, EGFR, VEGF, HIF-1α, and p53 in head and neck squamous cell carcinoma. Mol Imaging Biol. 2019;21(2):368–374.
25.
Surov A, Meyer HJ, Höhn AK, Wienke A, Sabri O, Purz S. 18F-FDG-PET can predict microvessel density in head and neck squamous cell carcinoma. Cancers (Basel) 2019;11:E543.
26.
TianMZhangHNakasoneY, et al.
Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging2004;
31:5–12.
27.
YamadaTUchidaMKwang-LeeK, et al.
Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas.Oral Surg Oral Med Oral Pathol Oral Radiol2012;
113:464–71.
28.
YokoboriYToyodaMSakakuraK, et al. (
18)F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma. Acta Otolaryngol2015;
135:494–499.
29.
ZhaoKYangSYZhouSH, et al.
Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter-1 and hypoxia-inducible-factor-1α and the phosphoinositide 3-kinase/protein kinase B pathway. Oncol Lett2014;
7:984–990.
30.
MoherDLiberatiATetzlaffJAltmanDG.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009;
6:e1000097.
31.
WhitingPRutjesAWReitsmaJB, et al.
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol2003;
3:25.
32.
ChalkidouALandauDBOdellEW, et al.
Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer2012;
48:3499–3513.
33.
LeeflangMMDeeksJJGatsonisCBossuytPM.Systematic reviews of diagnostic test accuracy. Ann Intern Med2008;
149:889–897.
34.
ZamoraJAbrairaVMurielA, et al.
Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol2006;
6:31.
35.
DerSimonianRLairdN.Meta-analysis in clinical trials. Control Clin Trials1986;
7:177–188.
36.
AlbadariNDengSLiW.The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov2019;
14:667–682.
37.
HicklinDJEllisLM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol2005;
23:1011–1027.
38.
WarburgO.On the origin of cancer cells. Science1956;
123:309–314.
39.
AlmangushAHeikkinenIMäkitieAA, et al.
Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis. Br J Cancer2017;
117:856–866.
40.
HeXChenZFuT, et al.
Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer2014;
14:1–13.
41.
FischerCAJungMZlobecI, et al.
Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis. Head Neck2011;
33:267–273.
42.
HynesNEHorschKOlayioyeMA, et al.
The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer2001;
8:151–159.
43.
RautavaJJeeKJMiettinenPJ, et al.
ERBB receptors in developing, dysplastic and malignant oral epithelia. Oral Oncol2008;
44:227–235.
44.
SineviciNO’SullivanJ.Oral cancer: Deregulated molecular events and their use as biomarkers. Oral Oncol2016;
61:12–18.
45.
TandonSTudur-SmithCRileyRD, et al.
A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev2010;
19:574–587.
46.
ZangJLiCZhaoLN, et al.
Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis. Head Neck2013;
35:1507–1514.
47.
XiaXDuRZhaoL, et al.
Expression of AEG-1 and microvessel density correlates with metastasis and prognosis of oral squamous cell carcinoma. Hum Pathol2014;
45:858–865.
48.
MarioniGMarinoFGiacomelliL, et al.
Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol2006;
126:633–639.
49.
GongLZhangWZhouJ, et al.
Prognostic value of hifs expression in head and neck cancer: a systematic review. PLoS One2013;
8:e75094.
50.
Surov A, Meyer HJ, Höhn AK, Schob S, Winter K, Sabri O, Purz S. Metabolo-volumetric parameters of 18F-FDG-PET can predict expression of EGFR and HIF 1alpha in uterine cervical cancer. Cancer Biomark 2019;24:135–140.
51.
Surov A, Meyer HJ, Wienke A. Standardized uptake values derived from 18F-FDG PET may predict lung cancer microvessel density and expression of KI 67, VEGF, and HIF-1α but not expression of cyclin D1, PCNA, EGFR, PD L1, and p53. Contrast Media Mol Imaging 2018;2018:9257929.
52.
KapplerMPabstUWeinholdtC, et al.
Causes and consequences of a glutamine induced normoxic HIF1 activity for the tumor metabolism. Int J Mol Sci2019;
20:4742.
53.
DengSMZhangWZhangB, et al.
Correlation between the uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the expression of proliferation-associated antigen Ki-67 in cancer patients: a meta-analysis. PLoS One2015;
10:e0129028.
54.
WuestMHamannIBouvetV, et al.
Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: A Multitracer Positron Emission Tomography Imaging Study in Mice. Mol Pharmacol2018;
93:79–89.
55.
El-ChemalySMalideDYaoJ, et al.
Glucose transporter-1 distribution in fibrotic lung disease: association with [18F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. Chest2013;
143:1685–1691.
56.
Ramos-GarcíaPGonzález-MolesMÁGonzález-RuizL, et al.
Prognostic and clinicopathological significance of cyclin D1 expression in oral squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol2018;
83:96–106.
57.
MarioniGD’AlessandroEBertolinA, et al.
Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges. Acta Otolaryngol2010;
130:4–9.
58.
CaoYChanKIXiaoG, et al.
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer2019;
19:1022.
59.
LiaoSPenneyBCWroblewskiK, et al.
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging2012;
39:27–38.
60.
KitaoTShigaTHirataK, et al.
Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas. Ann Nucl Med2019;
33:22–31.
61.
KroenkeMHirataKGafitaA, et al.
Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer. PLoS One2019;
14:e0213111.
62.
MeyerHJLeifelsLHamerlaG, et al.
ADC-histogram analysis in head and neck squamous cell carcinoma. Associations with different histopathological features including expression of EGFR, VEGF, HIF-1alpha, Her 2 and p53. A preliminary study. Magn Reson Imaging2018;
54:214–217.
63.
ChanMWHigginsKEnepekidesD, et al.
Radiologic differences between human papillomavirus-related and human papillomavirus-unrelated oropharyngeal carcinoma on diffusion-weighted imaging. ORL J Otorhinolaryngol Relat Spec2016;
78:344–352.
